Loading…
Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model
We have used Syrian hamsters to examine the role of pre-existing immunity to adenovirus (Ad) 5 in the toxicity of the oncolytic Ad vector INGN 007. Groups of hamsters were or were not immunized with Ad5. Half the hamsters were immunosuppressed using cyclophosphamide (CP), then injected intravenously...
Saved in:
Published in: | Molecular therapy 2009-10, Vol.17 (10), p.1724-1732 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313 |
---|---|
cites | cdi_FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313 |
container_end_page | 1732 |
container_issue | 10 |
container_start_page | 1724 |
container_title | Molecular therapy |
container_volume | 17 |
creator | Dhar, Debanjan Spencer, Jacqueline F Toth, Karoly Wold, William SM |
description | We have used Syrian hamsters to examine the role of pre-existing immunity to adenovirus (Ad) 5 in the toxicity of the oncolytic Ad vector INGN 007. Groups of hamsters were or were not immunized with Ad5. Half the hamsters were immunosuppressed using cyclophosphamide (CP), then injected intravenously (i.v.) with 3× the maximum tolerated dose (MTD) of INGN 007 (in immunocompetent hamsters), and toxicity and vector replication in the liver were quantitated. In nonimmunized immunocompetent hamsters, toxicity was observed early but the hamsters recovered by day 6 after vector injection. In nonimmunized immunosuppressed hamsters, the vector was lethal by 3 days. Pre-existing neutralizing antibody (NAb) prevented liver infection and hepatotoxicity in both immunocompetent and immunosuppressed hamsters. In another study, passive immunization of immunosuppressed hamsters 1 day before a lethal dose (1× MTD) of INGN 007 prevented liver infection and replication, but immunization 1 day after vector administration was barely effective. When immunosuppressed hamsters were passively immunized 1 day after injection of 1/3rd the MTD of INGN 007, then significant protection was observed against liver infection and toxicity. Therefore, serum NAb are sufficient to prevent oncolytic Ad vector liver infection and toxicity. We saw no evidence that pre-existing immunity was associated with increased vector toxicity. |
doi_str_mv | 10.1038/mt.2009.156 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2835003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1525001616321360</els_id><sourcerecordid>4072869381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313</originalsourceid><addsrcrecordid>eNptkVFrFDEQx4MotlaffNeAj7Jnskn2Ni9COdQWKi1YfQ3ZZLZNuU1qkl16H8NvbJY9rhV8mmHym_9M5o_QW0pWlLD205BXNSFyRUXzDB1TUYuKkJo_P-S0OUKvUrorGRWyeYmOqGxILWV7jP5cRajgwaXs_A0-H4bRu7zD2lt8pVNyEzwWc8CnFnyYXBwTFri0TuBzwtfhwZmZ2OgxgcXdLIAvvQnbXXbmadcvMDlE7DzOt4B_7KIr5JkeUoaIvwcL29foRa-3Cd7s4wn6-fXL9easurj8dr45vaiM4DxXjLWcME4l523f1J21HWFrwQ1hVNs157QH2Zl1bawlhJvO9L1urDVUGssZZSfo86J7P3YDWFN-EvVW3Uc36LhTQTv174t3t-omTKpumSCEFYEPe4EYfo-QsroLY_RlZ0XXshatbBkp1MeFMjGkFKE_TKBEzf6pIavZP1X8K_S7p0s9snvDCvB-AbzOY4QDMORZY5EQCwHleJODqJJx4A1YF8vxlQ3uv6P_AioItgg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1792589830</pqid></control><display><type>article</type><title>Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model</title><source>Open Access: PubMed Central</source><creator>Dhar, Debanjan ; Spencer, Jacqueline F ; Toth, Karoly ; Wold, William SM</creator><creatorcontrib>Dhar, Debanjan ; Spencer, Jacqueline F ; Toth, Karoly ; Wold, William SM</creatorcontrib><description>We have used Syrian hamsters to examine the role of pre-existing immunity to adenovirus (Ad) 5 in the toxicity of the oncolytic Ad vector INGN 007. Groups of hamsters were or were not immunized with Ad5. Half the hamsters were immunosuppressed using cyclophosphamide (CP), then injected intravenously (i.v.) with 3× the maximum tolerated dose (MTD) of INGN 007 (in immunocompetent hamsters), and toxicity and vector replication in the liver were quantitated. In nonimmunized immunocompetent hamsters, toxicity was observed early but the hamsters recovered by day 6 after vector injection. In nonimmunized immunosuppressed hamsters, the vector was lethal by 3 days. Pre-existing neutralizing antibody (NAb) prevented liver infection and hepatotoxicity in both immunocompetent and immunosuppressed hamsters. In another study, passive immunization of immunosuppressed hamsters 1 day before a lethal dose (1× MTD) of INGN 007 prevented liver infection and replication, but immunization 1 day after vector administration was barely effective. When immunosuppressed hamsters were passively immunized 1 day after injection of 1/3rd the MTD of INGN 007, then significant protection was observed against liver infection and toxicity. Therefore, serum NAb are sufficient to prevent oncolytic Ad vector liver infection and toxicity. We saw no evidence that pre-existing immunity was associated with increased vector toxicity.</description><identifier>ISSN: 1525-0016</identifier><identifier>EISSN: 1525-0024</identifier><identifier>DOI: 10.1038/mt.2009.156</identifier><identifier>PMID: 19602998</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenoviridae - immunology ; Adenoviruses ; Animals ; Antibodies ; Antibodies, Neutralizing - immunology ; Cancer therapies ; Chemotherapy ; Clinical trials ; Cricetinae ; Cyclophosphamide - pharmacology ; Drug dosages ; Female ; Genes ; Genetic Vectors - immunology ; Genetic Vectors - toxicity ; Immunity - drug effects ; Immunity - physiology ; Immunocompetence ; Immunology ; Immunosuppressive Agents - pharmacology ; Infections ; Leukocytes ; Liver ; Liver - drug effects ; Liver - metabolism ; Mesocricetus ; Oncolytic Virotherapy - adverse effects ; Oncolytic Virotherapy - methods ; Original ; Toxicity ; Tumors ; Viruses</subject><ispartof>Molecular therapy, 2009-10, Vol.17 (10), p.1724-1732</ispartof><rights>2009 The American Society of Gene & Cell Therapy</rights><rights>Copyright Nature Publishing Group Oct 2009</rights><rights>Copyright 2009, The American Society of Gene & Cell Therapy 2009 The American Society of Gene & Cell Therapy</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313</citedby><cites>FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835003/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835003/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19602998$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dhar, Debanjan</creatorcontrib><creatorcontrib>Spencer, Jacqueline F</creatorcontrib><creatorcontrib>Toth, Karoly</creatorcontrib><creatorcontrib>Wold, William SM</creatorcontrib><title>Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model</title><title>Molecular therapy</title><addtitle>Mol Ther</addtitle><description>We have used Syrian hamsters to examine the role of pre-existing immunity to adenovirus (Ad) 5 in the toxicity of the oncolytic Ad vector INGN 007. Groups of hamsters were or were not immunized with Ad5. Half the hamsters were immunosuppressed using cyclophosphamide (CP), then injected intravenously (i.v.) with 3× the maximum tolerated dose (MTD) of INGN 007 (in immunocompetent hamsters), and toxicity and vector replication in the liver were quantitated. In nonimmunized immunocompetent hamsters, toxicity was observed early but the hamsters recovered by day 6 after vector injection. In nonimmunized immunosuppressed hamsters, the vector was lethal by 3 days. Pre-existing neutralizing antibody (NAb) prevented liver infection and hepatotoxicity in both immunocompetent and immunosuppressed hamsters. In another study, passive immunization of immunosuppressed hamsters 1 day before a lethal dose (1× MTD) of INGN 007 prevented liver infection and replication, but immunization 1 day after vector administration was barely effective. When immunosuppressed hamsters were passively immunized 1 day after injection of 1/3rd the MTD of INGN 007, then significant protection was observed against liver infection and toxicity. Therefore, serum NAb are sufficient to prevent oncolytic Ad vector liver infection and toxicity. We saw no evidence that pre-existing immunity was associated with increased vector toxicity.</description><subject>Adenoviridae - immunology</subject><subject>Adenoviruses</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Cricetinae</subject><subject>Cyclophosphamide - pharmacology</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Genes</subject><subject>Genetic Vectors - immunology</subject><subject>Genetic Vectors - toxicity</subject><subject>Immunity - drug effects</subject><subject>Immunity - physiology</subject><subject>Immunocompetence</subject><subject>Immunology</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Infections</subject><subject>Leukocytes</subject><subject>Liver</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Mesocricetus</subject><subject>Oncolytic Virotherapy - adverse effects</subject><subject>Oncolytic Virotherapy - methods</subject><subject>Original</subject><subject>Toxicity</subject><subject>Tumors</subject><subject>Viruses</subject><issn>1525-0016</issn><issn>1525-0024</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNptkVFrFDEQx4MotlaffNeAj7Jnskn2Ni9COdQWKi1YfQ3ZZLZNuU1qkl16H8NvbJY9rhV8mmHym_9M5o_QW0pWlLD205BXNSFyRUXzDB1TUYuKkJo_P-S0OUKvUrorGRWyeYmOqGxILWV7jP5cRajgwaXs_A0-H4bRu7zD2lt8pVNyEzwWc8CnFnyYXBwTFri0TuBzwtfhwZmZ2OgxgcXdLIAvvQnbXXbmadcvMDlE7DzOt4B_7KIr5JkeUoaIvwcL29foRa-3Cd7s4wn6-fXL9easurj8dr45vaiM4DxXjLWcME4l523f1J21HWFrwQ1hVNs157QH2Zl1bawlhJvO9L1urDVUGssZZSfo86J7P3YDWFN-EvVW3Uc36LhTQTv174t3t-omTKpumSCEFYEPe4EYfo-QsroLY_RlZ0XXshatbBkp1MeFMjGkFKE_TKBEzf6pIavZP1X8K_S7p0s9snvDCvB-AbzOY4QDMORZY5EQCwHleJODqJJx4A1YF8vxlQ3uv6P_AioItgg</recordid><startdate>20091001</startdate><enddate>20091001</enddate><creator>Dhar, Debanjan</creator><creator>Spencer, Jacqueline F</creator><creator>Toth, Karoly</creator><creator>Wold, William SM</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><general>Nature Publishing Group</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20091001</creationdate><title>Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model</title><author>Dhar, Debanjan ; Spencer, Jacqueline F ; Toth, Karoly ; Wold, William SM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adenoviridae - immunology</topic><topic>Adenoviruses</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Cricetinae</topic><topic>Cyclophosphamide - pharmacology</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Genes</topic><topic>Genetic Vectors - immunology</topic><topic>Genetic Vectors - toxicity</topic><topic>Immunity - drug effects</topic><topic>Immunity - physiology</topic><topic>Immunocompetence</topic><topic>Immunology</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Infections</topic><topic>Leukocytes</topic><topic>Liver</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Mesocricetus</topic><topic>Oncolytic Virotherapy - adverse effects</topic><topic>Oncolytic Virotherapy - methods</topic><topic>Original</topic><topic>Toxicity</topic><topic>Tumors</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dhar, Debanjan</creatorcontrib><creatorcontrib>Spencer, Jacqueline F</creatorcontrib><creatorcontrib>Toth, Karoly</creatorcontrib><creatorcontrib>Wold, William SM</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dhar, Debanjan</au><au>Spencer, Jacqueline F</au><au>Toth, Karoly</au><au>Wold, William SM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model</atitle><jtitle>Molecular therapy</jtitle><addtitle>Mol Ther</addtitle><date>2009-10-01</date><risdate>2009</risdate><volume>17</volume><issue>10</issue><spage>1724</spage><epage>1732</epage><pages>1724-1732</pages><issn>1525-0016</issn><eissn>1525-0024</eissn><abstract>We have used Syrian hamsters to examine the role of pre-existing immunity to adenovirus (Ad) 5 in the toxicity of the oncolytic Ad vector INGN 007. Groups of hamsters were or were not immunized with Ad5. Half the hamsters were immunosuppressed using cyclophosphamide (CP), then injected intravenously (i.v.) with 3× the maximum tolerated dose (MTD) of INGN 007 (in immunocompetent hamsters), and toxicity and vector replication in the liver were quantitated. In nonimmunized immunocompetent hamsters, toxicity was observed early but the hamsters recovered by day 6 after vector injection. In nonimmunized immunosuppressed hamsters, the vector was lethal by 3 days. Pre-existing neutralizing antibody (NAb) prevented liver infection and hepatotoxicity in both immunocompetent and immunosuppressed hamsters. In another study, passive immunization of immunosuppressed hamsters 1 day before a lethal dose (1× MTD) of INGN 007 prevented liver infection and replication, but immunization 1 day after vector administration was barely effective. When immunosuppressed hamsters were passively immunized 1 day after injection of 1/3rd the MTD of INGN 007, then significant protection was observed against liver infection and toxicity. Therefore, serum NAb are sufficient to prevent oncolytic Ad vector liver infection and toxicity. We saw no evidence that pre-existing immunity was associated with increased vector toxicity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>19602998</pmid><doi>10.1038/mt.2009.156</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1525-0016 |
ispartof | Molecular therapy, 2009-10, Vol.17 (10), p.1724-1732 |
issn | 1525-0016 1525-0024 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2835003 |
source | Open Access: PubMed Central |
subjects | Adenoviridae - immunology Adenoviruses Animals Antibodies Antibodies, Neutralizing - immunology Cancer therapies Chemotherapy Clinical trials Cricetinae Cyclophosphamide - pharmacology Drug dosages Female Genes Genetic Vectors - immunology Genetic Vectors - toxicity Immunity - drug effects Immunity - physiology Immunocompetence Immunology Immunosuppressive Agents - pharmacology Infections Leukocytes Liver Liver - drug effects Liver - metabolism Mesocricetus Oncolytic Virotherapy - adverse effects Oncolytic Virotherapy - methods Original Toxicity Tumors Viruses |
title | Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T08%3A36%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pre-existing%20Immunity%20and%20Passive%20Immunity%20to%20Adenovirus%205%20Prevents%20Toxicity%20Caused%20by%20an%20Oncolytic%20Adenovirus%20Vector%20in%20the%20Syrian%20Hamster%20Model&rft.jtitle=Molecular%20therapy&rft.au=Dhar,%20Debanjan&rft.date=2009-10-01&rft.volume=17&rft.issue=10&rft.spage=1724&rft.epage=1732&rft.pages=1724-1732&rft.issn=1525-0016&rft.eissn=1525-0024&rft_id=info:doi/10.1038/mt.2009.156&rft_dat=%3Cproquest_pubme%3E4072869381%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1792589830&rft_id=info:pmid/19602998&rfr_iscdi=true |